Issues related to development of new antiseizure treatments

Authors

  • Karen S. Wilcox,

    Corresponding author
    • Anticonvulsant Drug Development Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah, U.S.A
    Search for more papers by this author
  • Tracy Dixon-Salazar,

    1. Department of Neuroscience, Howard Hughes Medical Institute, University of California, San Diego, La Jolla, California, U.S.A
    Search for more papers by this author
  • Graeme J. Sills,

    1. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
    Search for more papers by this author
  • Elinor Ben-Menachem,

    1. Institution for Clinical Neuroscience, Sahlgrenska Academy, University of Goteborg, Goteborg, Sweden
    Search for more papers by this author
  • H. Steve White,

    1. Anticonvulsant Drug Development Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah, U.S.A
    Search for more papers by this author
  • Roger J. Porter,

    1. Epilepsy Therapy Project and Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A
    Search for more papers by this author
  • Marc A. Dichter,

    1. Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A
    Search for more papers by this author
  • Solomon L. Moshé,

    1. Saul R. Korey Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
    2. Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
    3. Department of Pediatrics, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
    4. Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
    Search for more papers by this author
  • Jeffrey L. Noebels,

    1. Departments of Neurology, Neuroscience and Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, U.S.A
    Search for more papers by this author
  • Michael D. Privitera,

    1. Department of Neurology, University of Cincinnati, Cincinnati, Ohio, U.S.A
    Search for more papers by this author
  • Michael A. Rogawski

    1. Department of Neurology, University of California, Davis School of Medicine, Sacramento, California, U.S.A
    Search for more papers by this author

Address correspondence to Karen S. Wilcox, Anticonvulsant Drug Development Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT 84108, U.S.A. E-mail: karen.wilcox@hsc.utah.edu

Summary

This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)–funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.

Ancillary